Is Boston Scientific Positioned For a Decline?

Boston Scientific has rallied back to its highest levels since last year's financial crisis and is scheduled to discuss a key defibrillator trial this morning, prompting one large investor to position for a potential decline.

Volume in the September 11 puts climbed to 7,336 against open interest of 2,143 contracts. A large purchase for $0.20 accounted for most of the activity, according to OptionMonster's tracking systems.

Boston Scientific rose 2.71 percent to close at $11.75 yesterday and is up 6 percent in the last month. The heart device company will present final results for the trial of its MADIT-CRT defibrillator at 8 a.m. ET today. On June 24, management said the device met its primary endpoint by reducing heart failure.

The puts purchased yesterday will protect against a 6 percent drop in Boston Scientific shares.

Options Trading School:


Boston Scientific Competes With:

Johnson & Johnson


St. Jude Medical



David Russell is a reporter and writer for OptionMonster.